Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Flexi-Pricing Scheme Unveiled For Novartis AG (ADR) (NVS) Kisqali In The Face Of Stiff Competition

After recently getting the approval of the U.S. Food and Drug Administration, Novartis AG (ADR) (NYSE:NVS) has announced that a flexible pricing system will be applied for Kisqali.

The drug, which is used to treat metastatic breast cancer, is employing this strategy in a bid to get a share of the market that is currently dominated by Abemaciclib, a drug manufactured by Eli Lilly and Co (NYSE:LLY) and Ibrance, a drug manufactured by Pfizer Inc. (NYSE:PFE).

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, drugstore, service,

wavebreakmedia/Shutterstock.com

Wholesale Prices

The flexible pricing structure will see a supply of 28 days of the 600-mg dose cost $10,950 while a four-week supply of a 400-mg dose will be priced at $8,760. A four-week supply of a dose of 200-mg will be priced at $4,380. A spokesperson for Novartis AG (ADR) (NYSE:NVS) said that Kisqali’s wholesale prices were lower compared to those of its rivals.

“Kisqali will be the CDK 4/6 inhibitor with the lowest WAC price, and with the flexible pricing structure, we anticipate it will have an 18% to 20% lower aggregate cost based on the dosing seen in the trial,” said Novartis’ spokesperson.

Regulatory Conditions

Other than fierce competition in the market, the flexible pricing structure could have been inspired by the fact that the regulatory conditions for the use of Kisqali are tougher than those of its rivals. Prior to starting use of Kisqali, patients will be required to take an ECG test. The ECG test should also be taken on the 14th day during the first cycle as well as the beginning of cycle two. This is because mild cardiac arrhythmias were observed in the course of the clinical trials.

Last year, Novartis AG (ADR) (NYSE:NVS) entered into pay-for-performance agreements for its Entresto heart failure drug. In the deal, customers would only be required to pay for the value they received. The chief executive of the company, Joe Jimenez, is on record as predicting that the pricing environment will only get more difficult with ageing populations, especially in the United States.

In Wednesday’s trading session, shares of Novartis AG (ADR) (NYSE:NVS) edged up by 0.68% to close the day at $75.57.

Follow Novartis A G (NYSE:NVS)
Trade (NYSE:NVS) Now!

Note: This article is written by Andy Parker and was originally published at Market Exclusive.